<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01748162</url>
  </required_header>
  <id_info>
    <org_study_id>00059385</org_study_id>
    <nct_id>NCT01748162</nct_id>
  </id_info>
  <brief_title>Management of Recurrent Croup</brief_title>
  <official_title>Management of Recurrent Croup: Comparison Between Inhaled Fluticasone and Oral Prednisolone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Michigan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Presently children who experience recurring croup symptoms receive a variety of treatments.
      This is because it is not clear which treatments may be best. Some children are given inhaled
      steroids (similar to what children with asthma use). Others are carefully watched and
      cautioned to avoid potential triggers (certain foods, environmental allergens, etc), and
      should episodes of croup recur they are treated with a short course of oral steroids. The
      purpose of this study is to compare two safe and clinically appropriate methods for treating
      recurrent croup, daily inhaled steroids versus observation with oral steroids on an as needed
      basis, to see if either is useful in preventing future episodes of croup.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quantity of Recurrent Episodes</measure>
    <time_frame>1 year</time_frame>
    <description>Quantity of recurrent croup episodes experienced over a 1 year period by each participating subject.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Severity of Croup Episodes</measure>
    <time_frame>1 year</time_frame>
    <description>Severity of recurrent croup episodes based on Westley Croup scale (0 - 17, where 0 is mildest croup symptoms and 17 is most severe symptoms.)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Croup</condition>
  <arm_group>
    <arm_group_label>Inhaled steroids</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daily inhaled steroids. Fluticasone 2 puffs inhaled orally twice daily for six months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patient and clinician observation with short term oral prednisolone as needed. Offered at 1mg/kg (body weight) daily dosing for symptomatic treatment on as needed basis for three days, but may be modified per managing physician's discretion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluticasone</intervention_name>
    <description>Daily inhaled steroids. Fluticasone 2 puffs inhaled orally twice daily for six months.</description>
    <arm_group_label>Inhaled steroids</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisolone IF needed</intervention_name>
    <arm_group_label>Oral control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pediatric population: 6 months to 15 years of age

          -  2 or more episodes of croup in 12 month period

               -  croup defined as acute onset inspiratory stridor, barking cough, with respiratory
                  distress.

        Exclusion Criteria:

          -  Grade 3 or 4 subglottic stenosis

          -  Subglottic hemangioma

          -  Posterior laryngeal cleft

          -  Recurrent respiratory papillomatosis

          -  External compression (Innominate artery compression, mediastinal mass, (double aortic
             arch, etc)

          -  Symptoms or signs suggesting another cause of stridor, such as epiglottitis, bacterial
             tracheitis, or supraglottic foreign body

          -  Tracheomalacia/ bronchomalacia severe enough to cause respiratory distress

          -  Current steroid therapy for previously diagnosed condition, i.e. reactive airway
             disease.

          -  Other medical conditions necessitating chronic steroid utilization
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>15 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David J Brown, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan Department of Otolaryngology-Head &amp; Neck Surgery</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.facebook.com/MichiganOtolaryngology</url>
    <description>Please visit our Department Facebook page for information regarding the study</description>
  </link>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 31, 2012</study_first_submitted>
  <study_first_submitted_qc>December 10, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 12, 2012</study_first_posted>
  <results_first_submitted>October 2, 2017</results_first_submitted>
  <results_first_submitted_qc>November 1, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">November 13, 2017</results_first_posted>
  <last_update_submitted>November 1, 2017</last_update_submitted>
  <last_update_submitted_qc>November 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Michigan</investigator_affiliation>
    <investigator_full_name>David Brown</investigator_full_name>
    <investigator_title>Associate Professor of Otorhinolaryngology</investigator_title>
  </responsible_party>
  <keyword>croup</keyword>
  <keyword>recurrent croup</keyword>
  <keyword>barky cough</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Croup</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Fluticasone</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>10 participants were recruited and consented and had their initial baseline bronchoscopy, but of the 5 at 1 site, only 1 had an actual croup episode within he first 6 months. Because of decreased recruitment, the study was terminated. The other site's data is not fully available due to unexpected staff turnover and systems failures.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Inhaled Steroids</title>
          <description>Daily inhaled steroids. Fluticasone 2 puffs inhaled orally twice daily for six months.
Fluticasone: Daily inhaled steroids. Fluticasone 2 puffs inhaled orally twice daily for six months.</description>
        </group>
        <group group_id="P2">
          <title>Oral Control</title>
          <description>Short term oral prednisolone. Offered at 1mg/kg daily dosing for symptomatic treatment on as needed basis for three days, but may be modified per managing physician's discretion.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Started 6 Month Initial Treatment Plan</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed 6 Month Initial Treatment</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Started 6 Month Followup</title>
              <participants_list>
                <participants group_id="P1" count="0">No participants in either arm had additional croup episodes in the first 6 months; study terminated.</participants>
                <participants group_id="P2" count="0">No participants in either arm had additional croup episodes in the first 6 months; study terminated.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>no additional croup episodes to evaluate</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>participant consented but did not begin</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>reasons not available</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Inhaled Steroids</title>
          <description>Daily inhaled steroids. Fluticasone 2 puffs inhaled orally twice daily for six months.
Fluticasone: Daily inhaled steroids. Fluticasone 2 puffs inhaled orally twice daily for six months.</description>
        </group>
        <group group_id="B2">
          <title>Oral Control</title>
          <description>Short term oral prednisolone. Offered at 1mg/kg daily dosing for symptomatic treatment on as needed basis for three days, but may be modified per managing physician's discretion.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <description>Age brackets of children participating:</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>6 months to 15 years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="5"/>
                    <count group_id="B2" value="5"/>
                    <count group_id="B3" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <population>Due to unexpected staff turnover, data from one site is incomplete.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="2"/>
                    <count group_id="B2" value="3"/>
                    <count group_id="B3" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="5"/>
                    <count group_id="B2" value="5"/>
                    <count group_id="B3" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Quantity of Recurrent Episodes</title>
        <description>Quantity of recurrent croup episodes experienced over a 1 year period by each participating subject.</description>
        <time_frame>1 year</time_frame>
        <population>No participants completed to 1 year because of early study termination.</population>
        <group_list>
          <group group_id="O1">
            <title>Inhaled Steroids</title>
            <description>Daily inhaled steroids. Fluticasone 2 puffs inhaled orally twice daily for six months.
Fluticasone: Daily inhaled steroids. Fluticasone 2 puffs inhaled orally twice daily for six months.</description>
          </group>
          <group group_id="O2">
            <title>Oral Control</title>
            <description>Short term oral prednisolone. Offered at 1mg/kg daily dosing for symptomatic treatment on as needed basis for three days, but may be modified per managing physician's discretion.</description>
          </group>
        </group_list>
        <measure>
          <title>Quantity of Recurrent Episodes</title>
          <description>Quantity of recurrent croup episodes experienced over a 1 year period by each participating subject.</description>
          <population>No participants completed to 1 year because of early study termination.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Severity of Croup Episodes</title>
        <description>Severity of recurrent croup episodes based on Westley Croup scale (0 - 17, where 0 is mildest croup symptoms and 17 is most severe symptoms.)</description>
        <time_frame>1 year</time_frame>
        <population>No participants completed to 1 year because of early study termination.</population>
        <group_list>
          <group group_id="O1">
            <title>Inhaled Steroids</title>
            <description>Daily inhaled steroids. Fluticasone 2 puffs inhaled orally twice daily for six months.
Fluticasone: Daily inhaled steroids. Fluticasone 2 puffs inhaled orally twice daily for six months.</description>
          </group>
          <group group_id="O2">
            <title>Oral Control</title>
            <description>Short term oral prednisolone. Offered at 1mg/kg daily dosing for symptomatic treatment on as needed basis for three days, but may be modified per managing physician's discretion.</description>
          </group>
        </group_list>
        <measure>
          <title>Severity of Croup Episodes</title>
          <description>Severity of recurrent croup episodes based on Westley Croup scale (0 - 17, where 0 is mildest croup symptoms and 17 is most severe symptoms.)</description>
          <population>No participants completed to 1 year because of early study termination.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Six months (because study was terminated based on no participants having additional episodes).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Inhaled Steroids</title>
          <description>Daily inhaled steroids. Fluticasone 2 puffs inhaled orally twice daily for six months.
Fluticasone: Daily inhaled steroids. Fluticasone 2 puffs inhaled orally twice daily for six months.</description>
        </group>
        <group group_id="E2">
          <title>Oral Control</title>
          <description>Short term oral prednisolone. Offered at 1mg/kg daily dosing for symptomatic treatment on as needed basis for three days, but may be modified per managing physician's discretion.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. David J. Brown</name_or_title>
      <organization>University of Michigan</organization>
      <email>davidjb@med.umich.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

